Should I buy or sell Biomea Fusion stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks .

What is Biomea Fusion's stock price target for 2024?

8 analysts have issued 1 year target prices for Biomea Fusion's shares. Their BMEA share price targets range from $14.00 to $90.00. On average, they predict the company's stock price to reach $53.13 in the next twelve months. This suggests a possible upside of 362.0% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts .

How have BMEA shares performed in 2024?

Biomea Fusion's stock was trading at $14.52 on January 1st, 2024. Since then, BMEA shares have decreased by 20.8% and is now trading at $11.50. View the best growth stocks for 2024 here .

Are investors shorting Biomea Fusion?

Biomea Fusion saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,240,000 shares, an increase of 18.2% from the March 15th total of 11,200,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 13.0 days. Currently, 47.8% of the company's stock are sold short. View Biomea Fusion's Short Interest .

When is Biomea Fusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our BMEA earnings forecast .

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04.

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Biomea Fusion's stock is owned by many different institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle , Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann . View institutional ownership trends .

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BMEA

Biomea Fusion (BMEA) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Buy BMEA with Qtrade

Free BMEA Stock Alerts

$11.50

-0.45 (-3.77%)

(As of 04/17/2024 ET)

Compare

Today's Range: $11.44
▼
$12.10
50-Day Range: $11.50
▼
$18.85
52-Week Range: $8.13
▼
$43.69

Volume: 802,854 shs
Average Volume: 990,263 shs
Market Capitalization: $412.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.13

Get Biomea Fusion alerts:

Biomea Fusion MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 362.0% Upside
$53.13 Price Target
Short Interest: Bearish
47.76% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.01
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.25) to ($3.94) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.74 out of 5 stars

Medical Sector

619th out of 913 stocks

Pharmaceutical Preparations Industry

265th out of 398 stocks

3.4

Analyst's Opinion

Consensus Rating
Biomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biomea Fusion has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
47.76% of the float of Biomea Fusion has been sold short.
Short Interest Ratio / Days to Cover
Biomea Fusion has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.
Change versus previous month
Short interest in Biomea Fusion has recently increased by 18.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biomea Fusion does not currently pay a dividend.
Dividend Growth
Biomea Fusion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BMEA.

2.8

News and Social Media Coverage

News Sentiment
Biomea Fusion has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Biomea Fusion this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
MarketBeat Follows
Only 16 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -16% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biomea Fusion insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.27% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biomea Fusion are expected to grow in the coming year, from ($4.25) to ($3.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biomea Fusion is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biomea Fusion is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Biomea Fusion has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Biomea Fusion Stock (NASDAQ:BMEA)

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

BMEA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BMEA Stock News Headlines

April 16, 2024 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Sees Significant Growth in Short Interest

April 11, 2024 | americanbankingnews.com

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Recommendation of "Moderate Buy" by Analysts

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 4, 2024 | msn.com

3 Best Stocks to Buy Now, 4/4/2024, According to Top Analysts

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial Position

April 1, 2024 | globenewswire.com

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024 | investorplace.com

BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023

April 1, 2024 | benzinga.com

Recap: Biomea Fusion Q4 Earnings

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 1, 2024 | globenewswire.com

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

April 1, 2024 | globenewswire.com

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

March 17, 2024 | finance.yahoo.com

BMEA Apr 2024 5.000 put

March 17, 2024 | finance.yahoo.com

BMEA Apr 2024 5.000 call

March 7, 2024 | investorplace.com

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

March 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Trial Outcomes and Strong Safety Profile

March 6, 2024 | finance.yahoo.com

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

March 6, 2024 | globenewswire.com

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

March 1, 2024 | markets.businessinsider.com

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | globenewswire.com

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 27, 2024 | seekingalpha.com

Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research

February 19, 2024 | markets.businessinsider.com

Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For

February 18, 2024 | investorplace.com

3 Speculative Stocks That Could Make Your February Unforgettable

February 7, 2024 | markets.businessinsider.com

Dissecting My Biomea Fusion (NASDAQ:BMEA) Options Trade: Tips, Tricks, and Lessons Learned

January 10, 2024 | theglobeandmail.com

Wall Street Expects 190% Upside for This Biotech Stock

January 9, 2024 | finanznachrichten.de

Biomea Fusion, Inc.: Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

January 9, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Biomea Fusion Amid Promising Clinical Trials

See More Headlines

Receive BMEA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BMEA
CUSIP: N/A
CIK: 1840439
Web: www.biomeafusion.com
Phone: 650-980-9099
Fax: N/A
Employees: 103
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $53.13
High Stock Price Target: $90.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +362.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-117,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -69.35%
Return on Assets: -59.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.84
Quick Ratio: 7.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.74 per share
Price / Book: 2.43

Miscellaneous

Outstanding Shares: 35,890,000
Free Float: 26,461,000
Market Cap: $412.74 million
Optionable: Optionable
Beta: -0.53

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Thomas Andrew Butler (Age 43)
Co-Founder, Chairman & CEO
Comp: $921.14k
Mr. Ramses M. Erdtmann (Age 61)
Co-Founder, President, COO & Director
Comp: $659.53k
Mr. Franco Valle (Age 43)
CFO & Principal Accounting Officer
Comp: $651.77k
Mr. Heow Tan (Age 65)
Chief Technology & Quality Officer
Ms. Naomi Cretcher
Chief People Officer
Dr. Thorsten Kirschberg Ph.D. (Age 54)
Executive Vice President of Chemistry
Dr. Stephan Morris M.D.
Chief Development Officer
Mr. Ravi Upasani
Executive Vice President of Intellectual Property
Dr. Juan Pablo Frias M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BMEA Stock Analysis - Frequently Asked Questions

Should I buy or sell Biomea Fusion stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares.
View BMEA analyst ratings or view top-rated stocks.
What is Biomea Fusion's stock price target for 2024?: 8 analysts have issued 1 year target prices for Biomea Fusion's shares. Their BMEA share price targets range from $14.00 to $90.00. On average, they predict the company's stock price to reach $53.13 in the next twelve months. This suggests a possible upside of 362.0% from the stock's current price.
View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts.
How have BMEA shares performed in 2024?: Biomea Fusion's stock was trading at $14.52 on January 1st, 2024. Since then, BMEA shares have decreased by 20.8% and is now trading at $11.50.
View the best growth stocks for 2024 here.
Are investors shorting Biomea Fusion?: Biomea Fusion saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 13,240,000 shares, an increase of 18.2% from the March 15th total of 11,200,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is presently 13.0 days. Currently, 47.8% of the company's stock are sold short.
View Biomea Fusion's Short Interest.
When is Biomea Fusion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our BMEA earnings forecast.

How were Biomea Fusion's earnings last quarter?: Biomea Fusion, Inc. (NASDAQ:BMEA) issued its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04.
When did Biomea Fusion IPO?: Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO.
Who are Biomea Fusion's major shareholders?: Biomea Fusion's stock is owned by many different institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Global Healthcare Ma Cormorant, Michael JM Hitchcock and Rainer M Erdtmann.
View institutional ownership trends.
How do I buy shares of Biomea Fusion?: Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMEA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biomea Fusion (BMEA) Stock Price, News & Analysis

Biomea Fusion MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biomea Fusion Stock (NASDAQ:BMEA)

BMEA Stock Price History

BMEA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BMEA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™